Drug intelligence / Profile preview

IL2110

Development stage: Preclinical
Lead developer: iLeadBMS
Modality: Small Molecules
Administration: Oral

Overview

IL2110 (also known as IL-2110) is a preclinical-stage small molecule inhibitor of the NLRP3 inflammasome, originally developed by Ildong Pharmaceutical and currently being developed by its spin-off biotech, iLeadBMS. The NLRP3 inflammasome is a multiprotein complex that plays a critical role in the innate immune response by activating caspase-1, which in turn processes the pro-inflammatory cytokines IL-1β and IL-18, and induces pyroptosis. Dysregulation of NLRP3 is implicated in various neuroinflammatory and autoimmune conditions. IL2110 is being investigated for the treatment of neuroinflammatory and autoimmune disorders, with a primary focus on multiple sclerosis (MS).

Other names: IL 2110IL2110IL-2110

Targets

NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)

Beyond the preview

Go deeper on IL2110.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IL2110.

Explore the full profile